1 / 16

Founded in 1960 £32M research commitment in 2012-13

Leukaemia & Lymphoma Research. Founded in 1960 £32M research commitment in 2012-13 The object for which LLR is established is the advancement of health and the saving of lives by:

chick
Download Presentation

Founded in 1960 £32M research commitment in 2012-13

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Leukaemia & Lymphoma Research • Founded in 1960 • £32M research commitment in 2012-13 • The object for which LLR is established is the advancement of health and the saving of lives by: • Promoting and assisting research into all aspects of blood cancers including the causes, diagnosis, treatment and cure of all blood cancers; and • Advancing the public understanding of blood cancers

  2. The LLR and Stem Cell Transplantation • £7.6M Currently invested in HSCT related research • CTRF • 6 trials • TARP • 6 projects • 4 Specialist Programmes

  3. The Need • The majority of adults with blood cancer die of relapsed or resistant disease. • Pipeline of targeted drug or transplant options urgently require assessment • Compared to Phase III trials in haemato-oncology the UK track record in early phase trials has been modest. • Absence of a co-ordinated networks with large enough catchment to allow rapid recruitment • The strategic advantage of a centrally imposed structure (NHS) has not been exploited

  4. Trials Acceleration Programme (TAP) Central Coordination Hub to manage TAP early phase trials PI Charlie Craddock A funded network of early phase leukaemia centres: Serving metropolitan areas within the UK-covering catchment area of >20 million Dedicated research nurses and data managers

  5. TAP Network - aims • To open 4/5 new trials each year • Open within 6 months • Recruit in timely fashion • To strengthen translational studies • To complete, analyse and publish results two years after recruitment of first patient • To achieve a steady state of 10/15 trials recruiting upwards of 700 patients over 3 years • Secure the future of Haem Onc trials in the UK

  6. Translational Work • Trials specific work • Biobanking (where available)

  7. Cancer Research UK Clinical Trials Unit (CRCTU) University of Birmingham NCRN Accredited, NIHR Registered Builds on LLR ‘s investment in early phase haematology trials TAP Central Coordination Hub

  8. TAP Central Coordination Hub • Statistical design • Regulatory approvals • Contracts & sponsorship • Site initiation • Trial management • Programming • Monitoring • Analysis • Publication

  9. Leukaemia Centres

  10. Progress • Award made in to establish hub in 2011 • Centre awards made in 2012 • Fully operational April-May 2012 • 16 applications processed • 12 accepted, 3 rejected, 1 withdrawn • Several other studies being developed • 4 trials open and recruiting well • Anticipate the opening of 5-7 more by spring 2014

  11. Trials Acceleration Programme (TAP) *Southampton General Hospital, Barts Hospital London, The Christie Manchester, King’s College London (King’s Guy’s, St Thomas’), St James’ University Hospital Leeds, Queen Elizabeth Hospital Birmingham, Hammersmith Hospital London, Belfast City Hospital, Gartnavel General Hospital Glasgow, Royal Liverpool University Hospital, Churchill Hospital Oxford, Cardiff University Hospital, Nottingham University Hospital

  12. Industry • Novartis • Merck • Celgene • Millennium • Gilead • Pharmacyclics • GSK • Ariad

  13. Novartis Feedback • Where TAP meets Novartis needs • Speed • Productivity • Recruitment • Costs • Trial access for patients • Patient access to treatment post study • Quality

  14. Other boxes ticked • Government drive to improve research environment in the UK • Reducing red tape for clinical trials

  15. Policy Impact • TAP policy dinners at Speakers House • Case Study in ‘Strategy for UK Life Sciences; One Year On’* • House of Lords Science and Technology Committee report Regenerative Medicine** • Case study ABPI/AMRC roundtable event at the Conservative Party conference 2013 * https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/36684/12-1346-strategy-for-uk-life-sciences-one-year-on.pdf ** http://www.publications.parliament.uk/pa/ld201314/ldselect/ldsctech/23/23.pdf

More Related